23ANDME A consumer genetics company with a mission to become the Google of personalized healthcare Halted in 2013 by the FDA because of regulatory concerns Was approved to re-launch a scaled-back version of its services in October 2015 A “poster child” for the healthcare consumer empowerment movement and, as well, for how challenging it is to innovate in healthcare Has endured twists and turns; provides 3 services today Genetic testing for consumers: 60+ reports in four categories Genetic-based, and other, data for researchers, drug developers, and scientists 23andMe Therapeutics for in-house drug development Today the company has more than 1.2 million customers worldwide and partnerships with Pfizer, Genentech, and others $225 million in funding; valued at more than $1 billion Sept 2016: Began offering standalone ancestry product for $99